Roche: The US and Asia outsprint Europe in life science sector
Slow regulatory processes and an unwillingness to pay the price for new medicines are contributing factors to Europe losing its significance as the home of drug development, criticizes Roche CEO.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Europe risks losing the race to win the favor of pharmaceutical companies, CEO at Roche Severin Schwan tells business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
